| Date | Title | Description |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 21.01.2026 | GSK приобретает компанию RAPT Therapeutics за $2,2 млрд | Сделка, одна из первых крупных в 2026 году, предусматривает выплату $58,00 за акцию при закрытии сделки, что оценивает общий капитал компании примерно в $2,2 млрд. Это существенно выше стоимости акций RAPT на закрытии 16 января, которая сос... |
| 20.10.2025 | ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma | BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locall... |
| 14.10.2025 | 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China | In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome ... |
| 19.08.2025 | RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries | YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti... |
| 13.08.2025 | Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China | YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III cl... |
| 17.06.2025 | RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis | YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from Eu... |
| 03.06.2025 | 2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer | YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China ev... |
| 12.05.2025 | Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Prim... | YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: ... |
| 09.04.2025 | Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis | YANTAI, China, April 9, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with gener... |
| 15.02.2025 | ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer | YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng ... |
| 08.01.2025 | Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma | YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (de... |
| 13.12.2024 | 2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis | YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("R... |
| 29.10.2024 | RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China | YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ®... |
| 06.08.2024 | First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis | YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targe... |
| 05.06.2024 | RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment | YANTAI, China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatmen... |
| 04.06.2024 | RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 | YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-l... |
| 21.05.2024 | RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome | YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), th... |
| 10.05.2024 | RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing | The biotech company continues to offer hope to systemic lupus erythematosus (SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept
YANTAI, China, May 10, 2024 /PRNewswire/ -- Rem... |
| 03.04.2024 | RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome | YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food a... |
| 11.03.2024 | RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 | YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the ... |
| 02.02.2024 | World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap | YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap ... |
| 12.01.2024 | RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients | YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (M... |
| 18.12.2023 | RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients | YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mecha... |
| 28.11.2023 | RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO) | YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, sing... |
| 15.11.2023 | RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology | YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial ... |
| 27.09.2023 | Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis | YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that Telitacicept(RC18)... |
| 25.07.2023 | RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal | YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has announced that their Phase II clinical ... |
| 10.07.2023 | RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors | The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes
YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "... |
| 05.06.2023 | RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name | The "B" marker is removed from the Company's stock short name
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a fully-integrated commercial-sta... |
| 05.06.2023 | ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer | YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab ved... |
| 26.04.2023 | RemeGen Celebrates World Intellectual Property Day 2023 | YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, is celebrating World Intellectual Property Day 2023 which fal... |
| 28.02.2023 | On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy | YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare dis... |
| 13.12.2022 | RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA | YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug c... |
| 02.04.2020 | RemeGen Closes Over USD $100M Funding Round | RemeGen, a Yantai, China-based biopharmaceutical company, closed an approximately USD $100m private financing round.
The round was co-led by Lilly Asia Ventures and Lake Bleu Capital with participation from Vivo Capital, Janchor Partners, O... |
| 02.04.2020 | RemeGen Completes USD $100 Million Plus in Funding | - |
| - | Potential new treatment option could mean good news for lupus patients | With limited treatment options currently available for patients diagnosed with systemic lupus erythematosus (SLE), known more commonly as lupus — a chronic autoimmune disease1 — a potential new medicine could be a game-changer for patients ... |
